- NicOx
-
NicOx S.A. Type Société Anonyme Industry Pharmaceuticals Founded 1996 Headquarters Sophia Antipolis, France Key people Michele Garufi (Chairman of the board) Products Naproxcinod Revenue 
€3,36 million (2009)Net income €73,887 million (2008)Total equity €102,069 million (2009)Employees 133 (2009) Subsidiaries NicOx Research Institute Srl, NicOx Inc. Website nicox.com NicOx S.A. is a French pharmaceutical company. Its headquarters are at Sophia Antipolis (U.S. headquarters in Warren, New Jersey, opened in October 2007). Louis Ignarro, co-recipient of the 1998 Nobel Prize in Physiology or Medicine for demonstrating the signalling properties of nitric oxide, is a member of the scientific committee of the company.
The company focuses on the uses of the medical properties of nitric oxide. It has several molecules in the pipeline, and its lead compound was an anti-inflammatory drug, naproxcinod, of the CINOD (COX-inhibiting nitric oxide donator) class for the treatment of osteoarthritis. This class of drugs was first described by John Wallace[1] and colleagues.[2] The company has ongoing development partnerships with Bausch & Lomb and Merck.[3]
The market capitalisation of the company was $ 1 billion as of January 2008. It is listed on Euronext, the French stock exchange and is part of the CAC Mid 100 stock market index. It has been included in the SBF 120 index since 18 June 2007. Oppenheimer Funds is its first shareholder with 25 % of its capital.
Naproxcinod
Naproxcinod was the company's lead compound until 2011. The company finished three phase III clinical trials. The first of these studies to be published showed that naproxcinod had similar efficacy to naproxen (measured in WOMAC Pain, function and patient global assessment) in controlling signs and symptoms of osteoarthritis.[4] It has been well documented that non-steroidal anti-inflammatory drugs increase blood pressure, and naproxen is one of the safest in this regard.[5] Meanwhile naproxcinod had similar effects on blood pressure to placebo (which is considered neutral), while the comparator naproxen (sold under the brand Aleve in the United States) showed a statistically significant increase in blood pressure. This difference was especially marked for those patients taking RAS blockers (ACE inhibitors, ARBs and beta blockers). This means that naproxcinod could have become an option for patients with osteoarthritis who needed to take NSAIDs.
In September of 2009, NicOx filed for regulatory approval of naproxcinod with the United States Food and Drug Administration (FDA) and the European Medicines Agency. On 12 May 2010, an FDA advisory committee voted against approval, questioning the safety of the drug. NicOx has appealed this decision.[3] Subsequently, in April 2011, the company withdrew its European application after it became clear that an EU expert panel was going to fail to render a positive review of NicOx's clinical data.[3]
References
- ^ John L. Wallace homepage at Farncombe Institute, McMaster University
- ^ Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G (July 1994). "Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat". Gastroenterology 107 (1): 173–179. PMID 8020659.
- ^ a b c "NicOx pulls drug application, shares plunge". Reuters. 20 April 2011. http://www.reuters.com/article/2011/04/20/nicox-idUSLDE73J0IG20110420. Retrieved 21 April 2011.
- ^ William B. White; Thomas J. Schnitzer; Rosana Fleming; Brigitte Duquesroix; Maarten Beekman (5 May 2009), "Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Versus Naproxen on Systemic Blood Pressure in Patients With Osteoarthritis", American Journal of Cardiology (Elsevier) 104 (6): 840–845, 15 September 2009, ISSN 1879-1913, OCLC 39263367, http://www.ajconline.org/article/S0002-9149(09)01049-2/abstract, retrieved 21 April 2011
- ^ Frishman, William H. (21 March 2002), "Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema", American Journal of Cardiology (Elsevier) 89 (6): 18–25, ISSN 1879-1913, OCLC 39263367, http://www.ajconline.org/article/S0002-9149(02)02233-6/abstract, retrieved 21 April 2011
External links
CAC Small companies of France (18 October 2011)AB Science • ABC Arbitrage • Acanthe Développement • Acteos • Actia Group • ADL Partner • ADT SIIC • Aedian • Affine • AffiParis • Afone • Akka Technologies • Compagnie des Alpes • Alpha MOS • Altamir Amboise • ANF Immobilier • Anovo • April Group • Archos • Argan • Artprice.com • Assystem • AST Groupe • Atari • Aubay • Audika • Aufeminin.com • Augros Cosmetics • Aurea • Aures Technologies • Ausy • Avanquest Software • Avenir Finance • Avenir Telecom • Aviation Latécoère • Axway Software • Barbara Bui • Bastide Le Confort • BCI Navigation • Le Belier • Belvédère • BigBen Interactive • BioAlliance Pharma • Boiron • Bonduelle • Bourse Direct • Boursorama • Business & Decision • Cameleon Software • Canal+ Group • Capelli • Cast • Catering International & Services • Cegedim • Cegid Group • CFCAL Banque • Chargeurs • Cibox Interactive • Coheris • Compagnie Marocaine • Courtois • Cottin Frères • CS Communication & Systèmes • Cybergun • Cybernetix • Dalet • Dane Elec Memory • Delachaux • Delfingen • Delta Plus Group • Devoteam • Diagnostic Medical Systems • DNXcorp • Ebizcuss.com • ECA • Egide • Electricité et Eaux de Madagascar • Encres Dubuit • Entrepose Contracting • ESI Group • ESR • Etam Développement • Euro Disney • Euro Ressources • Euromedis Groupe • EuropaCorp • Exel Industries • Fala • Fauvet Girel • Fimalac • Financière Marjos • Fleury Michon • Foncière Inéa • Foncière Paris France • Gameloft • Gascogne • Grenobloise d'Electronique et d'Automatismes • GECI International • Generix • GFI Informatique • GL Events • GPE Groupe Pizzorno • Groupe Crit • Groupe Flo • Groupe Gorgé • Groupe JAJ • Groupe Open • Groupe Partouche • Guerbet • Guillemot Corporation • Guy Degrenne • Guyenne et Gascogne • Haulotte Group • Henri Maire • HF Company • Hi-Media • HighCo • Hiolle Industries • Hologram Industries • Hubwoo • IEC Professionnel Media • IGE+XAO • Index Multimedia • Info Vista • Infotel • Innate Pharma • Innelec Multimedia • Inter Parfums • Internationale de Plantations d'Hévéas • IT Link • Itesoft • ITS Group • Jacquet Metal Service • Kaufman et Broad • Keyrus • Kindy • La Perla World • LaCie • Lacroix • Lafuma • Laurent-Perrier • LDLC.com • Le Noble Age • Lectra • Les Nouveaux Constructeurs • Lexibook Linguistic Electronic System • Linedata Services • Lisi • LVL Médical Groupe • Maisons France Confort • Manitou BF • Mecelec • Medasys • Medica • Memscap • Mersen • Metabolic Explorer • MGI Coutier • Micropole • Montaigne Fashion Group • Montupet • Naturex • Netgem • Neurones • NextRadioTV • NicOx • Norbert Dentressangle • Novagali Pharma • NRJ Group • Oeneo • OL Groupe • Orapi • Orchestra Kazibao • Osiatis • Outside Living Industries • Overlap Groupe • Oxymetal • Parrot • Parsys • PCAS • Gérard Perrier Industrie • Pharmagest Interactive • Pierre & Vacances • Plastiques du Val de Loire • Poncin Yachts • Precia • Prismaflex International • Prologue • PSB Industries • Public Systeme Hopscotch • Quantel • Recyclex • Rentabiliweb • Riber • Risc Group • Rodriguez Group • Rougier • Rue du Commerce • Sartorius Stedim Biotech • SCBSM • Séché Environnement • Séchilienne-Sidec • Securidev • Sequana • SII • SMTPC • Soditech Ingénierie • Soft Computing • Sogeclair • Solucom • Sopra Group • Spir Communication • SQLI • Stallergenes • S.T. Dupont • Stentys • Store Electronics • Sword Group • Synergie • Systar • Terreis • Tessi • Theolia • Thermocompact • Tonna Electronique • Touax • Toupargel Groupe • Transgene • Trigano • U10 • Umanis • Union Financière de France Banque • Union Technologies Informatique • Universal Multimédia • Valtech • Vet'Affaires • Vilmorin & Cie. • Visiodent • Vivalis • Vranken-Pommery Monopole • Xilam Animation • Züblin Immobilière
Categories:- Pharmaceutical companies of France
- SBF 120
Wikimedia Foundation. 2010.
